157 related articles for article (PubMed ID: 30152102)
1. Hereditary cancer screening: Case reports and review of literature on ten Ashkenazi Jewish founder mutations.
Cox DM; Nelson KL; Clytone M; Collins DL
Mol Genet Genomic Med; 2018 Nov; 6(6):1236-1242. PubMed ID: 30152102
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of nonfounder BRCA1/2 mutations in Ashkenazi Jewish patients presenting for genetic testing at a hereditary breast and ovarian cancer center.
Frey MK; Kopparam RV; Ni Zhou Z; Fields JC; Buskwofie A; Carlson AD; Caputo T; Holcomb K; Chapman-Davis E
Cancer; 2019 Mar; 125(5):690-697. PubMed ID: 30480775
[TBL] [Abstract][Full Text] [Related]
3. Cancer Susceptibility Genetic Testing in a High-Risk Cohort of Urban Ashkenazi Jewish Individuals.
Nielsen SM; De Simone LM; Olopade OI
J Genet Couns; 2018 Dec; 27(6):1405-1410. PubMed ID: 29946849
[TBL] [Abstract][Full Text] [Related]
4. Genetic Predisposition to Breast Cancer Due to Mutations Other Than BRCA1 and BRCA2 Founder Alleles Among Ashkenazi Jewish Women.
Walsh T; Mandell JB; Norquist BM; Casadei S; Gulsuner S; Lee MK; King MC
JAMA Oncol; 2017 Dec; 3(12):1647-1653. PubMed ID: 28727877
[TBL] [Abstract][Full Text] [Related]
5. Incidence of BRCA1 and BRCA2 non-founder mutations in patients of Ashkenazi Jewish ancestry.
Rosenthal E; Moyes K; Arnell C; Evans B; Wenstrup RJ
Breast Cancer Res Treat; 2015 Jan; 149(1):223-7. PubMed ID: 25476495
[TBL] [Abstract][Full Text] [Related]
6. Founder mutations in BRCA1/2 are not frequent in Canadian Ashkenazi Jewish men with prostate cancer.
Hamel N; Kotar K; Foulkes WD
BMC Med Genet; 2003 Aug; 4():7. PubMed ID: 12911837
[TBL] [Abstract][Full Text] [Related]
7. Retrospective Cohort Study on the Limitations of Direct-to-Consumer Genetic Screening in Hereditary Breast and Ovarian Cancer.
Desai NV; Barrows ED; Nielsen SM; Hatchell KE; Anderson MJ; Haverfield EV; Herrera B; Esplin ED; Lucassen A; Tung NM; Isaacs C
JCO Precis Oncol; 2023 Aug; 7():e2200695. PubMed ID: 37535880
[TBL] [Abstract][Full Text] [Related]
8. BRCA1 and BRCA2 germline mutations are frequently demonstrated in both high-risk pancreatic cancer screening and pancreatic cancer cohorts.
Lucas AL; Frado LE; Hwang C; Kumar S; Khanna LG; Levinson EJ; Chabot JA; Chung WK; Frucht H
Cancer; 2014 Jul; 120(13):1960-7. PubMed ID: 24737347
[TBL] [Abstract][Full Text] [Related]
9. The founder Ashkenazi Jewish mutations in the MSH2 and MSH6 genes in Israeli patients with gastric and pancreatic cancer.
Laitman Y; Herskovitz L; Golan T; Kaufman B; Paluch SS; Friedman E
Fam Cancer; 2012 Jun; 11(2):243-7. PubMed ID: 22219001
[TBL] [Abstract][Full Text] [Related]
10. Similar prevalence of founder BRCA1 and BRCA2 mutations among Ashkenazi and non-Ashkenazi men with breast cancer: evidence from 261 cases in Israel, 1976-1999.
Chodick G; Struewing JP; Ron E; Rutter JL; Iscovich J
Eur J Med Genet; 2008; 51(2):141-7. PubMed ID: 18158280
[TBL] [Abstract][Full Text] [Related]
11. Population testing for cancer predisposing BRCA1/BRCA2 mutations in the Ashkenazi-Jewish community: a randomized controlled trial.
Manchanda R; Loggenberg K; Sanderson S; Burnell M; Wardle J; Gessler S; Side L; Balogun N; Desai R; Kumar A; Dorkins H; Wallis Y; Chapman C; Taylor R; Jacobs C; Tomlinson I; McGuire A; Beller U; Menon U; Jacobs I
J Natl Cancer Inst; 2015 Jan; 107(1):379. PubMed ID: 25435541
[TBL] [Abstract][Full Text] [Related]
12. Identifying Ashkenazi Jewish BRCA1/2 founder variants in individuals who do not self-report Jewish ancestry.
Tennen RI; Laskey SB; Koelsch BL; McIntyre MH; Tung JY
Sci Rep; 2020 May; 10(1):7669. PubMed ID: 32376921
[TBL] [Abstract][Full Text] [Related]
13. Absence of genomic BRCA1 and BRCA2 rearrangements in Ashkenazi breast and ovarian cancer families.
Stadler ZK; Saloustros E; Hansen NA; Schluger AE; Kauff ND; Offit K; Robson ME
Breast Cancer Res Treat; 2010 Sep; 123(2):581-5. PubMed ID: 20221693
[TBL] [Abstract][Full Text] [Related]
14. Relative contributions of BRCA1 and BRCA2 mutations to "triple-negative" breast cancer in Ashkenazi Women.
Comen E; Davids M; Kirchhoff T; Hudis C; Offit K; Robson M
Breast Cancer Res Treat; 2011 Aug; 129(1):185-90. PubMed ID: 21394499
[TBL] [Abstract][Full Text] [Related]
15. Haplotype structure in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers.
Im KM; Kirchhoff T; Wang X; Green T; Chow CY; Vijai J; Korn J; Gaudet MM; Fredericksen Z; Shane Pankratz V; Guiducci C; Crenshaw A; McGuffog L; Kartsonaki C; Morrison J; Healey S; Sinilnikova OM; Mai PL; Greene MH; Piedmonte M; Rubinstein WS; ; Hogervorst FB; Rookus MA; Collée JM; Hoogerbrugge N; van Asperen CJ; Meijers-Heijboer HE; Van Roozendaal CE; Caldes T; Perez-Segura P; Jakubowska A; Lubinski J; Huzarski T; Blecharz P; Nevanlinna H; Aittomäki K; Lazaro C; Blanco I; Barkardottir RB; Montagna M; D'Andrea E; ; Devilee P; Olopade OI; Neuhausen SL; Peissel B; Bonanni B; Peterlongo P; Singer CF; Rennert G; Lejbkowicz F; Andrulis IL; Glendon G; Ozcelik H; ; Toland AE; Caligo MA; ; Beattie MS; Chan S; ; Domchek SM; Nathanson KL; Rebbeck TR; Phelan C; Narod S; John EM; Hopper JL; Buys SS; Daly MB; Southey MC; Terry MB; Tung N; Hansen TV; Osorio A; Benitez J; Durán M; Weitzel JN; Garber J; Hamann U; ; Peock S; Cook M; Oliver CT; Frost D; Platte R; Evans DG; Eeles R; Izatt L; Paterson J; Brewer C; Hodgson S; Morrison PJ; Porteous M; Walker L; Rogers MT; Side LE; Godwin AK; Schmutzler RK; Wappenschmidt B; Laitman Y; Meindl A; Deissler H; Varon-Mateeva R; Preisler-Adams S; Kast K; Venat-Bouvet L; Stoppa-Lyonnet D; Chenevix-Trench G; Easton DF; Klein RJ; Daly MJ; Friedman E; Dean M; Clark AG; Altshuler DM; Antoniou AC; Couch FJ; Offit K; Gold B
Hum Genet; 2011 Nov; 130(5):685-99. PubMed ID: 21597964
[TBL] [Abstract][Full Text] [Related]
16. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
[TBL] [Abstract][Full Text] [Related]
17. BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer.
Moslehi R; Chu W; Karlan B; Fishman D; Risch H; Fields A; Smotkin D; Ben-David Y; Rosenblatt J; Russo D; Schwartz P; Tung N; Warner E; Rosen B; Friedman J; Brunet JS; Narod SA
Am J Hum Genet; 2000 Apr; 66(4):1259-72. PubMed ID: 10739756
[TBL] [Abstract][Full Text] [Related]
18. Population screening for BRCA1/BRCA2 founder mutations in Ashkenazi Jews: proactive recruitment compared with self-referral.
Lieberman S; Tomer A; Ben-Chetrit A; Olsha O; Strano S; Beeri R; Koka S; Fridman H; Djemal K; Glick I; Zalut T; Segev S; Sklair M; Kaufman B; Lahad A; Raz A; Levy-Lahad E
Genet Med; 2017 Jul; 19(7):754-762. PubMed ID: 27929526
[TBL] [Abstract][Full Text] [Related]
19. The founder mutation MSH2*1906G-->C is an important cause of hereditary nonpolyposis colorectal cancer in the Ashkenazi Jewish population.
Foulkes WD; Thiffault I; Gruber SB; Horwitz M; Hamel N; Lee C; Shia J; Markowitz A; Figer A; Friedman E; Farber D; Greenwood CM; Bonner JD; Nafa K; Walsh T; Marcus V; Tomsho L; Gebert J; Macrae FA; Gaff CL; Paillerets BB; Gregersen PK; Weitzel JN; Gordon PH; MacNamara E; King MC; Hampel H; De La Chapelle A; Boyd J; Offit K; Rennert G; Chong G; Ellis NA
Am J Hum Genet; 2002 Dec; 71(6):1395-412. PubMed ID: 12454801
[TBL] [Abstract][Full Text] [Related]
20. Identification of germline genetic mutations in patients with pancreatic cancer.
Salo-Mullen EE; O'Reilly EM; Kelsen DP; Ashraf AM; Lowery MA; Yu KH; Reidy DL; Epstein AS; Lincoln A; Saldia A; Jacobs LM; Rau-Murthy R; Zhang L; Kurtz RC; Saltz L; Offit K; Robson ME; Stadler ZK
Cancer; 2015 Dec; 121(24):4382-8. PubMed ID: 26440929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
